Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells

Jessica Cantrell, Claire B Larmonier, Nona Janikashvili, Sara Bustamante, Jennifer Fraszczak, Amanda Herrell, Tamara Lundeen, Collin J LaCasse, Elaine Situ, Nicolas Larmonier, Emmanuel Katsanis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We have previously reported on the anti-tumoral potential of a chaperone-rich cell lysate (CRCL) vaccine. Immunization with CRCL generated from tumors elicits specific T and NK cell-dependent immune responses leading to protective immunity in numerous mouse tumor models. CRCL provides both a source of tumor antigens and danger signals leading to dendritic cell activation. In humans, tumor-derived CRCL induces dendritic cell activation and CRCL-loaded dendritic cells promote the generation of cytotoxic T lymphocytes in vitro. The current study was designed to identify the signaling events and modifications triggered by CRCL in antigen presenting cells. Our results indicate that tumor-derived CRCL not only promotes the activation of dendritic cells, but also significantly fosters the function of macrophages that thus appear as major targets of this vaccine. Activation of both cell types is associated with the induction of the MAP kinase pathway, the phosphorylation of STAT1, STAT5 and AKT and with transcription factor NF-κB activation in vitro and in vivo. These results thus provide important insights into the mechanisms by which CRCL-based vaccines exert their adjuvant effects on antigen presenting cells.

Original languageEnglish (US)
Pages (from-to)535-544
Number of pages10
JournalImmunobiology
Volume215
Issue number7
DOIs
StatePublished - Jul 2010

Fingerprint

Cancer Vaccines
Antigen-Presenting Cells
Dendritic Cells
Vaccines
Neoplasms
Cytotoxic T-Lymphocytes
Neoplasm Antigens
Natural Killer Cells
Immunity
Immunization
Transcription Factors
Phosphotransferases
Macrophages
Phosphorylation
T-Lymphocytes

Keywords

  • Cell signaling
  • Dendritic cells
  • Macrophages
  • Tumor vaccines

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Hematology
  • Medicine(all)

Cite this

Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells. / Cantrell, Jessica; Larmonier, Claire B; Janikashvili, Nona; Bustamante, Sara; Fraszczak, Jennifer; Herrell, Amanda; Lundeen, Tamara; J LaCasse, Collin; Situ, Elaine; Larmonier, Nicolas; Katsanis, Emmanuel.

In: Immunobiology, Vol. 215, No. 7, 07.2010, p. 535-544.

Research output: Contribution to journalArticle

Cantrell, J, Larmonier, CB, Janikashvili, N, Bustamante, S, Fraszczak, J, Herrell, A, Lundeen, T, J LaCasse, C, Situ, E, Larmonier, N & Katsanis, E 2010, 'Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells', Immunobiology, vol. 215, no. 7, pp. 535-544. https://doi.org/10.1016/j.imbio.2009.09.006
Cantrell J, Larmonier CB, Janikashvili N, Bustamante S, Fraszczak J, Herrell A et al. Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells. Immunobiology. 2010 Jul;215(7):535-544. https://doi.org/10.1016/j.imbio.2009.09.006
Cantrell, Jessica ; Larmonier, Claire B ; Janikashvili, Nona ; Bustamante, Sara ; Fraszczak, Jennifer ; Herrell, Amanda ; Lundeen, Tamara ; J LaCasse, Collin ; Situ, Elaine ; Larmonier, Nicolas ; Katsanis, Emmanuel. / Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells. In: Immunobiology. 2010 ; Vol. 215, No. 7. pp. 535-544.
@article{d8ad6d4834bf4e99b653c803d0d5ce61,
title = "Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells",
abstract = "We have previously reported on the anti-tumoral potential of a chaperone-rich cell lysate (CRCL) vaccine. Immunization with CRCL generated from tumors elicits specific T and NK cell-dependent immune responses leading to protective immunity in numerous mouse tumor models. CRCL provides both a source of tumor antigens and danger signals leading to dendritic cell activation. In humans, tumor-derived CRCL induces dendritic cell activation and CRCL-loaded dendritic cells promote the generation of cytotoxic T lymphocytes in vitro. The current study was designed to identify the signaling events and modifications triggered by CRCL in antigen presenting cells. Our results indicate that tumor-derived CRCL not only promotes the activation of dendritic cells, but also significantly fosters the function of macrophages that thus appear as major targets of this vaccine. Activation of both cell types is associated with the induction of the MAP kinase pathway, the phosphorylation of STAT1, STAT5 and AKT and with transcription factor NF-κB activation in vitro and in vivo. These results thus provide important insights into the mechanisms by which CRCL-based vaccines exert their adjuvant effects on antigen presenting cells.",
keywords = "Cell signaling, Dendritic cells, Macrophages, Tumor vaccines",
author = "Jessica Cantrell and Larmonier, {Claire B} and Nona Janikashvili and Sara Bustamante and Jennifer Fraszczak and Amanda Herrell and Tamara Lundeen and {J LaCasse}, Collin and Elaine Situ and Nicolas Larmonier and Emmanuel Katsanis",
year = "2010",
month = "7",
doi = "10.1016/j.imbio.2009.09.006",
language = "English (US)",
volume = "215",
pages = "535--544",
journal = "Immunobiology",
issn = "0171-2985",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "7",

}

TY - JOUR

T1 - Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells

AU - Cantrell, Jessica

AU - Larmonier, Claire B

AU - Janikashvili, Nona

AU - Bustamante, Sara

AU - Fraszczak, Jennifer

AU - Herrell, Amanda

AU - Lundeen, Tamara

AU - J LaCasse, Collin

AU - Situ, Elaine

AU - Larmonier, Nicolas

AU - Katsanis, Emmanuel

PY - 2010/7

Y1 - 2010/7

N2 - We have previously reported on the anti-tumoral potential of a chaperone-rich cell lysate (CRCL) vaccine. Immunization with CRCL generated from tumors elicits specific T and NK cell-dependent immune responses leading to protective immunity in numerous mouse tumor models. CRCL provides both a source of tumor antigens and danger signals leading to dendritic cell activation. In humans, tumor-derived CRCL induces dendritic cell activation and CRCL-loaded dendritic cells promote the generation of cytotoxic T lymphocytes in vitro. The current study was designed to identify the signaling events and modifications triggered by CRCL in antigen presenting cells. Our results indicate that tumor-derived CRCL not only promotes the activation of dendritic cells, but also significantly fosters the function of macrophages that thus appear as major targets of this vaccine. Activation of both cell types is associated with the induction of the MAP kinase pathway, the phosphorylation of STAT1, STAT5 and AKT and with transcription factor NF-κB activation in vitro and in vivo. These results thus provide important insights into the mechanisms by which CRCL-based vaccines exert their adjuvant effects on antigen presenting cells.

AB - We have previously reported on the anti-tumoral potential of a chaperone-rich cell lysate (CRCL) vaccine. Immunization with CRCL generated from tumors elicits specific T and NK cell-dependent immune responses leading to protective immunity in numerous mouse tumor models. CRCL provides both a source of tumor antigens and danger signals leading to dendritic cell activation. In humans, tumor-derived CRCL induces dendritic cell activation and CRCL-loaded dendritic cells promote the generation of cytotoxic T lymphocytes in vitro. The current study was designed to identify the signaling events and modifications triggered by CRCL in antigen presenting cells. Our results indicate that tumor-derived CRCL not only promotes the activation of dendritic cells, but also significantly fosters the function of macrophages that thus appear as major targets of this vaccine. Activation of both cell types is associated with the induction of the MAP kinase pathway, the phosphorylation of STAT1, STAT5 and AKT and with transcription factor NF-κB activation in vitro and in vivo. These results thus provide important insights into the mechanisms by which CRCL-based vaccines exert their adjuvant effects on antigen presenting cells.

KW - Cell signaling

KW - Dendritic cells

KW - Macrophages

KW - Tumor vaccines

UR - http://www.scopus.com/inward/record.url?scp=77953538002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953538002&partnerID=8YFLogxK

U2 - 10.1016/j.imbio.2009.09.006

DO - 10.1016/j.imbio.2009.09.006

M3 - Article

C2 - 19880213

AN - SCOPUS:77953538002

VL - 215

SP - 535

EP - 544

JO - Immunobiology

JF - Immunobiology

SN - 0171-2985

IS - 7

ER -